Alzheimer’s disease (AD) affects an estimated 18 million people and their families all over the world. While there is still no cure, participating in clinical trials can help future generations better understand and develop treatments for this debilitating condition.
Researchers at 25 clinics in the US are conducting a research study to test the safety and effectiveness of an injectable investigational treatment to determine if it can slow the rate of Alzheimer’s disease progression. We are looking for people with probable Alzheimer’s disease, and their caregivers, to participate.
Learn more about this AD study
You or someone in your care may be eligible to participate in this study.
Click the button above to answer a few questions to find out if you or someone in your care is eligible to participate in this AD study.
About this Study
You or the person in your care may be able to participate in this study. The people who may qualify for this study are:
- 50-89 years old
- Diagnosed with probable Alzheimer’s disease
- Living at home, or in a community dwelling, with an appropriate caregiver able to accompany the participant on all study visits as well as visit the participant at home at least 5 times a week
Study staff will review additional criteria at the first clinic visit.
What is Alzheimer’s Disease (AD)?
About 18 million people worldwide suffer from Alzheimer’s disease. Symptoms often include the progressive loss of memory and judgment, changes in personality, anxiety, or even suspiciousness and delusion.
Researchers are working hard to understand Alzheimer’s disease and to determine the best strategy to treat this difficult disease. Research aimed at finding out more about Alzheimer’s disease and potential new treatments is ongoing.What is the Purpose of this Clinical Research Study?
This study will test the safety and effectiveness of three different doses of an injectable investigational treatment against placebo (looks like the injectable investigational treatment but does not contain the active ingredient) to determine if it can slow the rate of Alzheimer’s disease progression.
Can I Enroll My Parent or Loved One in this Study?
Consent to participate in the study must be given by the patient or by his or her legal representative.
What is Expected of Study Participants?
All participants will continue on their usual AD treatment during the study. After an initial screening period of 4-7 weeks, qualified participants will be randomly assigned (by chance) to one of three doses of the injectable investigational treatment, or placebo (looks like the injectable investigational treatment but does not contain the active ingredient). Participants will continue on study treatment for up to 2 years.
Approximately once per month during the study, participants will need to visit the study clinic or be visited by study staff for tests and study procedures. Study procedures include urine and blood sample collections, MRI scans, PET scans, ECGs, AD assessments, and questionnaires. The primary caregiver will need to accompany the study participant for all study visits and procedures.
All study-related office visits, study-related evaluations, and study treatments will be provided at no cost. The study will not supply other AD medications that participants are already taking. After completing the study, participants may be eligible for an extension of the study.
No comments:
Post a Comment